A clinical trial testing Teitur Trophics‘ TT-P34 in Parkinson’s disease will use Neuralight‘s brain function biomarker based on eye movement to assess neural circuitry, the companies announced. Neuralight’s platform provides precise measures of brain function derived from eye movements, based on well-established links between specific eye movement…
News
A team at Michigan State University (MSU) won two grants to support research into portable devices designed to improve communication for people with Parkinson’s disease and atypical parkinsonism. Thea Knowles, PhD, assistant professor in MSU’s Department of Communicative Sciences and Disorders, is leading a team investigating the devices’ effectiveness at…
Light therapy using Celeste, Photopharmics’ investigational photo-neuromodulation device, was seen in a clinical trial to ease nonmotor symptoms in people with Parkinson’s disease, and to also improve quality of life for patients. Treatment also showed a trend toward reduced motor symptoms, the study’s main goal, although this effect…
The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) status to NouvNeu001, iRegene Therapeutics’ cell therapy for Parkinson’s disease. The FDA based its decision on data from a Phase 1/2 trial (NCT06167681) in China, which showed that the treatment eased motor symptoms in Parkinson’s…
BT-267, an LRRK2 inhibitor being developed by Brenig Therapeutics as a treatment for Parkinson’s disease, has reached sustained, clinically meaningful levels in the brain, according to early results from a study in healthy volunteers. The therapy is being developed for both idiopathic Parkinson’s, where the cause is…
Low muscle mass is more common in people with mild to moderate Parkinson’s disease than in those without the condition, especially in older men, a study found. While it was linked to a slightly larger blood pressure drop shortly after standing, it was not linked to more orthostatic symptoms,…
The American Parkinson Disease Association (APDA) is urging U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. to move forward with implementation of the National Parkinson’s Project. The project is an integrated national plan to prevent, diagnose, treat, and ultimately cure Parkinson’s disease.
Herantis Pharma has reported new Phase 1b biomarker data that support the expected mechanism of action of HER-096, its potential disease-modifying treatment for Parkinson’s disease. The Phase 1b trial (NCT06659562) evaluated the safety of HER-096 and explored early signs of biological activity in both healthy volunteers and…
GT-02287, an oral therapy being developed by Gain Therapeutics, was associated with improvements in motor function over three months in people with Parkinson’s disease, including participants both with and without GBA1 mutations. The findings come from an open-label Phase 1b trial (NCT06732180), which also showed lower levels…
Neuralight said a newly completed study showed its machine learning-based system monitoring eye movements via webcam is more sensitive than traditional tests used for tracking Parkinson’s disease progression. “For the first time, a biomarker has outperformed the neurological gold standard in tracking Parkinson’s disease over time, unlocking a new…
Recent Posts
- Merz honors resiliency of Parkinson’s community with new US campaign
- Lessons revealed in the quiet moments of Parkinson’s caregiving
- Gut immune cells may help Parkinson’s spread from the belly to the brain
- New delivery system guides curcumin to Parkinson’s-affected brain cells
- New $2M MJFF grant backs Parkinson’s walking study at Boston University